HOLX Add to watchlist $76.01 +0.00 (+0.00%) Last updated: Apr 16, 2026 00:47
52-Week Range
$76.01
$51.90 $76.01 $76.07

Fundamentals Overview

Hologic, Inc. is near the high of its 52-week range with premium valuation, trading relatively flat today.

Valuation premium

P/E 31.6 P/B 3.25 P/S 4.11

Intrinsic value (DCF)

+46.4% upside vs price

Profitability

Net margin 13.2%

Risk (Beta)

0.7 — lower vol

Earnings & growth

EPS $2.41 Rev -0.2% Profit -4.4% vs prior qtr

BullzEye Analysis

Our composite tilts Hold on technicals (e.g. RSI, ADX, trend), fundamentals, sentiment, sector and index context, and risk.

Composite Signal

Sell
Buy
Hold — 59% confidence Risk: Lower Volatility — Beta 0.7. Diversify and only invest what you can afford to lose.

Supporting (Buy):

DCF +46.4% upside vs price · 3M vs Healthcare sector: +7.6%

Pressures (Sell):

Sentiment weakening (6 downgrades)

Not financial advice. For education and research only; do your own research and consider a financial advisor before investing.

Key Stats

Market Cap
$16.97B
P/E (TTM)
31.57
EPS (TTM)
$2.41
Dividend Yield
N/A
52-Week Range
$51.90 - $76.07
Volume vs Avg
N/A
Beta
0.7

About

Hologic, Inc. develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment in the United States, Europe, the Asia-Pacific, and internationally. It operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. The company provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load tests for HIV, Hepatitis C, and Hepatitis...
Sector: Healthcare
Headquarters: US
Employees: 7,063
IPO Date: Mar 1990
Beta: 0.7 (Less volatile than market)

Ratings & Grades at a Glance

Recent institutional grades: majority downgrades. Current institutional positions: Buy: 2, Equal Weight: 4, Hold: 4, In Line: 4, Market Perform: 2, Neutral: 5, Outperform: 5, Overweight: 2, Sector Perform: 2.

Financial story & AI narrative

Open this tab to load the financial story.

Valuation & Ratios

Valuation, liquidity, and profitability metrics are consolidated here (including ratios that previously appeared in the Financials story). Trailing (TTM) vs forward-looking (e.g. DCF) is noted on each line where it matters.

DCF vs price: DCF estimate is $111.26; current price is $76.01. That’s a +46.4% gap. When the gap is large (e.g. >20%), that’s divergence; when they’re close, that’s convergence. Differences can reflect growth expectations, sector premiums, or conservative vs. optimistic assumptions. Use DCF as one input alongside technicals and sentiment.

Metric Value
Valuation
P/E (TTM) 31.57
DCF value (model) $111.26 (46.4% upside)
PEG (TTM) N/A
P/B (TTM) 3.25
P/S (TTM) 4.11
P/FCF (TTM) 16.98
Liquidity & enterprise
Current Ratio (TTM) 4.04
Quick Ratio (TTM) 3.32
Cash Ratio (TTM) 2.28
Profitability
ROE (TTM) N/A
ROA (TTM) N/A
Revenue growth (YoY) N/A
Net margin (TTM) 13.18%
Gross margin (TTM) 52.82%
Operating margin (TTM) 17.49%
Debt to equity (TTM) N/A

Latest News

News loads when you open this tab.

Price Target, Ratings & Grades

Analyst price targets, consensus, rating snapshot, and institutional grades for HOLX.

Analyst Sentiment at a Glance

Sentiment Weakening
Buy 2Equal Weight 4Hold 4In Line 4Market Perform 2Neutral 5Outperform 5Overweight 2Sector Perform 2
3 upgrades, 6 downgrades
Price Target Consensus
Current $76.01
Median $78.00
Consensus $77.75
Low consensus $76.00
High consensus $79.00

Stock Grades (Institutions)

Institution Action Previous Grade New Grade Date
Argus Research downgrade Buy Hold 2026-01-12
Evercore ISI Group downgrade Outperform In Line 2026-01-05
Morgan Stanley maintain Equal Weight Equal Weight 2025-11-11
Mizuho downgrade Outperform Neutral 2025-10-23
Raymond James downgrade Outperform Market Perform 2025-10-22
Stephens & Co. downgrade Overweight Equal Weight 2025-10-22
JP Morgan downgrade Overweight Neutral 2025-10-22
BTIG maintain Neutral Neutral 2025-10-21
Leerink Partners maintain Market Perform Market Perform 2025-10-21
Needham maintain Hold Hold 2025-10-21
Evercore ISI Group upgrade In Line Outperform 2025-10-07
Argus Research maintain Buy Buy 2025-09-19
Stephens & Co. maintain Overweight Overweight 2025-09-18
RBC Capital upgrade Sector Perform Outperform 2025-08-06
UBS maintain Neutral Neutral 2025-07-31
Morgan Stanley maintain Equal Weight Equal Weight 2025-07-31
Mizuho maintain Outperform Outperform 2025-07-16
Citigroup upgrade Neutral Buy 2025-07-09
Evercore ISI Group maintain In Line In Line 2025-07-08
Needham maintain Hold Hold 2025-05-28
Stephens & Co. maintain Overweight Overweight 2025-05-13
Morgan Stanley maintain Equal Weight Equal Weight 2025-05-05
Evercore ISI Group maintain In Line In Line 2025-05-02
Raymond James maintain Outperform Outperform 2025-05-02
RBC Capital maintain Sector Perform Sector Perform 2025-05-02
Needham maintain Hold Hold 2025-05-02
RBC Capital maintain Sector Perform Sector Perform 2025-04-08
Citigroup maintain Neutral Neutral 2025-03-04
Evercore ISI Group maintain In Line In Line 2025-02-06
Raymond James maintain Outperform Outperform 2025-02-06